選單 研討會快訊 最新醫療快訊 藥物安全警訊 學會行事曆 FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC Data from the phase 3 PALOMA-3 study support the approval of subcutaneous amivantamab in this NSCLC population. 2025-12-18 查看更多 FDA Grants Regular Approval to Rucaparib in Metastatic CRPC Findings from the phase 3 TRITON3 trial evaluating rucaparib in adult patients with metastatic BRCA-mutated CRPC supported the regulatory decision. 2025-12-18 查看更多 FDA Approves T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer 2025-12-16 查看更多 Pharmacists' Critical Role in Gene Therapy: Education, Collaboration, and Patient Care https://www.pharmacytimes.com/view/pharmacists-critical-role-in-gene-therapy-education-collaboration-and-patient-care 2025-10-16 查看更多 Navigating Novel Therapies: ADCs, BsAbs, and CAR T in RRMM Featured Video 2025-10-13 查看更多 PD-L1 Immunotherapy Advances in Gastroesophageal Malignancies 2025-08-04 查看更多 Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm) Advanced NSCLC: Final Overall Survival (OS) from the Phase 3 MARIPOSA Study Martin Dietrich, MD, PhD and Roy Herbst, MD discuss how the evolving first-line treatment options for EGFR-mutated non-small cell lung cancer, including osimertinib monotherapy, osimertinib plus chemotherapy, and amivantamab plus lazertinib, have reshaped the landscape, with a strong emphasis on overall survival benefits and the role of combination therapies in improving patient outcomes. Featured Video 2025-06-20 查看更多 Expert Panel: Role of Genomics and Genetics in Prostate Cancer Christopher Lee, MD; Alvaro Martinez, MD; Daniel Kim, MD, MBA; Steven E. Finkelstein, MD; and Dwight E. Heron, MD, MBA, FACRO, FACR, discuss how genomic and genetic research is revolutionizing our understanding of prostate cancer risk, progression, personalized treatment strategies, and potential targeted interventions by identifying specific genetic markers, inherited mutations, and molecular pathways that influence disease development and patient outcomes. Featured Video 2025-06-13 查看更多 123
